• Home
  • A-B index
  • Pharmacological Index
  • Drug Classes
  • Active Ingredients
  • Companies
  • News
  • Kogenate FS
    / Bayer


    Active Ingredient

    Status in Israel
    RX

    Presentation and Status in Health Basket

    Presentation Basket Yarpa Pharmasoft

    Vial

    1 x 500 IU

    partial basket chart 13841 11210, 11234

    Vial

    1 x 1,000 IU

    partial basket chart 13840 11233, 11211

    Related information


    Dosage

    See prescribing information for full details.


    Indications

    Treatment of classical hemophilia (hemophilia A) in which there is a demonstrated deficiency of activity of the plasma clotting factor FVIII.

     


    Contra-Indications

    Known intolerance or allergic reactions to constituents of the preparation. Known hypersensitivity to mouse or hamster protein may be contraindicated.


    Special Precautions

    FVIII deficiency should be proven prior to therapy. Patients treated with any AHF preparation should be carefully monitored for the development of antibodies to FVIII by appropriate clinical observation and laboratory tests. Pregnancy and lactation: Should be used during pregnancy and lactation only if clearly indicated.


    Side Effects

    Local injection site reactions, dizziness, rash.
    See prescribing information for full details.

     


    Drug interactions

    See prescribing information for full details.


    Manufacturer
    Bayer Healthcare LLC
    Licence holder
    CLOSE